Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Entera Bio (NASDAQ:ENTX)

Core Insights - Entera Bio Ltd. is set to achieve significant milestones in Q1 2026, focusing on the development of oral peptide therapies for osteoporosis and hypoparathyroidism [2][3] Group 1: Corporate Milestones - The company plans to submit its final Phase 3 protocol for EB613 to the FDA in Q1 2026, following a favorable FDA ruling on December 19, 2025 [4] - Results from the Phase 1 bridging study of Next-Gen EB613 are expected by the end of Q1 2026, indicating progress in the development of this next-generation candidate [5] - Entera aims to accelerate its hypoparathyroidism program in 2026, leveraging robust preclinical data for a long-acting PTH analog [6] Group 2: Product Development - EB613 is being developed as the first oral PTH(1-34) anabolic tablet treatment specifically for post-menopausal women with osteoporosis [4][6] - The company is also advancing its EB612 program, which focuses on an oral long-acting PTH(1-34) peptide tablet for patients with hypoparathyroidism [6] - Entera is exploring strategic partnerships to optimize the development and commercialization of its oral peptide programs [6] Group 3: Company Vision - Entera Bio is committed to addressing significant unmet medical needs through innovative oral peptide therapies, aiming to transform the standard of care in various therapeutic areas [7]